Management of Disseminated Intravascular Coagulation
The cornerstone of DIC management is aggressive treatment of the underlying disease, combined with supportive care using blood product transfusions based on specific thresholds and prophylactic anticoagulation in most cases. 1
Core Management Principles
1. Treat the Underlying Disease First
The single most important intervention is identifying and treating the underlying condition triggering DIC. This is exemplified by acute promyelocytic leukemia (APL), where early initiation of all-trans retinoic acid leads to rapid DIC resolution 1. Without addressing the root cause, supportive measures alone will fail as the coagulopathy perpetuates itself.
2. Blood Product Transfusion Thresholds
For Active Bleeding:
- Platelets: Transfuse to maintain count >50 × 10⁹/L 1
- Fresh Frozen Plasma (FFP): Give 15-30 mL/kg with careful clinical monitoring for volume overload 1
- Fibrinogen: If persistently <1.5 g/L despite FFP, transfuse two pools of cryoprecipitate or fibrinogen concentrate 1
For High Bleeding Risk (surgery/procedures) Without Active Bleeding:
Critical Caveat: Transfused platelets and fibrinogen have very short lifespans in DIC due to ongoing consumption from vigorous coagulation activation 1. Frequent monitoring and repeat dosing are often necessary.
3. Anticoagulation Strategy
Prophylactic anticoagulation with LMWH or UFH is recommended in all DIC patients EXCEPT:
- Platelet count <20 × 10⁹/L 1
- Active bleeding 1
- Hyperfibrinolytic DIC (avoid heparin in this subtype) 1
Choice of Heparin:
- LMWH preferred in most cases 1
- UFH preferred when high bleeding risk or renal failure present (easier reversibility) 1
For Therapeutic Anticoagulation (if thrombosis develops):
- Solid tumors: LMWH at full dose for 1 month, then 75% dose for 5 months 1
- Hematologic malignancies (APL): LMWH with frequent anti-Xa monitoring due to high bleeding risk 1
Important Note: Abnormal PT/PTT alone should NOT contraindicate anticoagulation in the absence of bleeding, as there is rebalanced hemostasis with parallel reduction in both clotting and anticlotting factors 1
4. Monitoring Requirements
Regular monitoring is essential:
- Blood counts and coagulation screen (frequency varies from daily to monthly based on clinical severity) 1
- Include fibrinogen and D-dimer measurements 1
- A ≥30% drop in platelet count suggests subclinical DIC even without clinical manifestations 1
What NOT to Use
Antifibrinolytics (Tranexamic Acid):
- NOT routinely recommended 1
- May increase thrombotic events 1
- Consider ONLY in therapy-resistant bleeding with hyperfibrinolytic DIC 1
Recombinant Factor VIIa:
- NOT recommended due to thrombotic risks and lack of RCT evidence 1
Anticoagulant Concentrates (antithrombin, activated protein C, thrombomodulin):
- No trials support their use in cancer-related DIC 1
Common Pitfalls to Avoid
- Ignoring the underlying disease: Supportive care alone is futile without treating the trigger
- Using fixed transfusion protocols: Thresholds must be adjusted based on bleeding status and underlying disease
- Withholding anticoagulation due to abnormal labs: Coagulopathy parameters alone are not contraindications if no active bleeding
- Routine use of antifibrinolytics: This can worsen outcomes except in specific hyperfibrinolytic scenarios
- Monitoring UFH with PTT in DIC: PTT may already be prolonged; use anti-FXa assays instead 1
Disease-Specific Considerations
The evidence provided focuses primarily on cancer-associated DIC [1-1], but the principles apply broadly. However, recognize that:
- APL requires more aggressive platelet support (higher thresholds) 1
- Hyperfibrinolytic DIC (common in APL, obstetric complications) requires avoiding heparin 1
- Septic DIC may present differently with only 50% showing abnormal coagulation screens 1
The management approach must be tailored to whether DIC presents as bleeding-predominant, thrombotic-predominant, or mixed phenotype, though the fundamental principles remain consistent across etiologies 2, 3, 4.